Alkem Laboratories Declares Interim Dividend of ₹43 per Share
Alkem Laboratories declared an interim dividend of ₹43 per equity share for FY2025-26. The company also approved its standalone and consolidated financial results for the quarter and nine months ended December 31, 2025. The dividend will be paid from March 6, 2026, with a record date of February 20, 2026.
The dividend payout is a direct financial benefit to shareholders, but the amount is not exceptionally large relative to the company's overall market capitalization. The approval of financial results is standard procedure.
The declaration of an interim dividend is a positive development for shareholders, indicating the company's financial health and commitment to returning value.
Alkem Laboratories Limited announced the outcome of its Board Meeting held on February 13, 2026. The Board approved the Standalone and Consolidated Unaudited Financial Results for the quarter and nine months ended December 31, 2025.
Additionally, the Board declared an interim dividend of ₹43 per equity share (representing 2150% on the face value of ₹2 per share) for the financial year 2025-2026. The payment of this interim dividend is scheduled to commence on March 6, 2026. The record date for the purpose of this dividend payment has been set as Friday, February 20, 2026.
The Board meeting commenced at 11:00 a.m. and concluded at 01:45 p.m.
What to do with a filing like this
Alkem Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under dividend. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Alkem Laboratories Limited. Read the original for the full detail.